Cargando…
High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
We investigated the serum concentration of endostatin in 84 patients with multiple myeloma (MM) and in 13 healthy controls. The level of measured anti-angiogenic agent was correlated with the phase and stage of the disease, and most importantly with clinical and laboratory parameters depicting the d...
Autores principales: | Urbańska-Ryś, Halina, Robak, Tadeusz |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781619/ https://www.ncbi.nlm.nih.gov/pubmed/14514474 http://dx.doi.org/10.1080/09629350310001599675 |
Ejemplares similares
-
The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020) -
Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
por: Gora-Tybor, Joanna, et al.
Publicado: (2003) -
Serum Endostatin Levels in Oral Squamous Cell Carcinoma
por: Mardani, Maryam, et al.
Publicado: (2018) -
The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021) -
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)